**Ranitidine**

**Section:** 17. Gastrointestinal medicines

### 17.1. Antiulcer medicines

- **Indication:** Gastro-oesophageal reflux disease
- **ICD11 code:** DA22.Z
- **INN:** Ranitidine
- **Medicine type:** Chemical agent
- **List type:** Core (EML) (EMLc)
- **Formulations:**
  - Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
  - Oral > Solid: 150 mg (as hydrochloride)
  - Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
- **EML status history:**
  - First added in 2003 (TRS 920)
  - Changed in 2007 (TRS 950)
  - Changed in 2021 (TRS 1035)
- **Sex:** All
- **Age:** Also recommended for children
- **Therapeutic alternatives:**
  - Medicines within the same pharmacological class can be used
- **Therapeutic alternatives limitations:**
  - Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)
- **Patent information:**
  - Patents have expired in most jurisdictions
  - Read more [about patents](#)

**Wikipedia:** [Ranitidine](#)

**DrugBank:** [Ranitidine](#)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, A02BA H2-receptor antagonists (excluding combinations), be specified as therapeutic alternatives under the square box listing for ranitidine on the EML and EMLc.